Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-088224
Filing Date
2024-07-31
Accepted
2024-07-31 06:55:07
Documents
73
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q syrs-20240630.htm   iXBRL 10-Q 1698146
2 EX-3.1 syrs-ex3_1.htm EX-3.1 265894
3 EX-10.1 syrs-ex10_1.htm EX-10.1 1174205
4 EX-10.2 syrs-ex10_2.htm EX-10.2 152212
5 EX-31.1 syrs-ex31_1.htm EX-31.1 15283
6 EX-31.2 syrs-ex31_2.htm EX-31.2 15389
7 EX-32.1 syrs-ex32_1.htm EX-32.1 7470
8 EX-32.2 syrs-ex32_2.htm EX-32.2 7439
  Complete submission text file 0000950170-24-088224.txt   9554407

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT syrs-20240630.xsd EX-101.SCH 1491437
76 EXTRACTED XBRL INSTANCE DOCUMENT syrs-20240630_htm.xml XML 1151233
Mailing Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140
Business Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140 617-744-1340
Syros Pharmaceuticals, Inc. (Filer) CIK: 0001556263 (see all company filings)

IRS No.: 453772460 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37813 | Film No.: 241159815
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)